Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer

Summary

A first-in-human study using NJH395 in non-breast HER2-positive advanced malignancies

Timeline

Start

2018-12-27

Primary completion

2020-10-19

Completion

2020-10-19

Publications

• Janku F, Han SW, Doi T, Amatu A, Ajani JA, Kuboki Y, Cortez A, Cellitti SE, Mahling PC, Subramanian K, Schoenfeld HA, Choi SM, Iaconis LA, Lee LH, Pelletier MR, Dranoff G, Askoxylakis V, Siena S. Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. Cancer Immunol Res. 2022 Dec 2;10(12):1441-1461. doi: 10.1158/2326-6066.CIR-21-0722.

Drugs

Indications